Target coverage and dose criteria based evaluation of the first clinical 1.5T MR-linac SBRT treatments of lymph node oligometastases compared with conventional CBCT-linac treatment.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Dennis WinkelPetra S Kroon

Abstract

Patients were treated at our institute for single and multiple lymph node oligometastases on the 1.5T MR-linac since August 2018. The superior soft-tissue contrast and additional software features of the MR-linac compared to CBCT-linacs allow for online adaptive treatment planning. The purpose of this study was to perform a target coverage and dose criteria based evaluation of the clinically delivered online adaptive radiotherapy treatment compared with conventional CBCT-linac treatment. Patient data was used from 14 patients with single lymph node oligometastases and 6 patients with multiple (2-3) metastases. All patients were treated on the 1.5T MR-linac with a prescribed dose of 5 × 7 Gy to 95% of the PTV and a CBCT-linac plan was created for each patient. The difference in target coverage between these plans was compared and plans were evaluated based on dose criteria for each fraction after calculating the CBCT-plan on the daily anatomy. The GTV coverage was evaluated based on the online planning and the post-delivery MRI. For both single and multiple lymph node oligometastases the GTV V35Gy had a median value of 100% for both the MR-linac plans and CBCT-plans pre- and post-delivery and did not significantly differ. The pe...Continue Reading

Citations

Sep 20, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Dennis WinkelPetra S Kroon
Sep 21, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Anita M Werensteijn-HoninghPetra S Kroon
Dec 22, 2020·Journal of Medical Imaging and Radiation Sciences·Abigael CloughCynthia L Eccles
Feb 20, 2021·Frontiers in Oncology·Juliane Hörner-RieberMarcel Verheij
Feb 25, 2021·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·S DingX Huang
Mar 26, 2021·Frontiers in Oncology·Daniela Thorwarth, Daniel A Low
Oct 12, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jan UnkelbachEliana Vasquez Osorio
Jun 17, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Lisa A MinDoenja M J Lambregts
May 26, 2021·Journal of Applied Clinical Medical Physics·Damodar PokhrelWilliam St Clair
Jun 24, 2021·Clinical and Translational Radiation Oncology·Enrica SeravalliGeert O Janssens
Jul 17, 2021·Journal of Cancer Research and Clinical Oncology·Francesco CucciaFilippo Alongi
Sep 2, 2021·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Fabian WeykampJuliane Hörner-Rieber
Nov 11, 2020·Clinical Oncology : a Journal of the Royal College of Radiologists·M Ingle, S Lalondrelle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
Anita M Werensteijn-HoninghIna M Jürgenliemk-Schulz
Clinical and Translational Radiation Oncology
Dennis WinkelIna M Jürgenliemk-Schulz
Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics
Noriyuki Kadoya
Technology in Cancer Research & Treatment
Haruo MatsushitaNoriyuki Kadoya
© 2021 Meta ULC. All rights reserved